The breakup of the Hisun-Pfizer JV typifies an unhappy marriage between Chinese and MNC pharma firms in the generics segment in recent years, although the two companies will continue to work as commercial partners under a new framework. Scrip delves into the reasons for the split and also outlines why, China is, nevertheless, expected to see more joint ventures for innovative drugs.

CDER now granting 86% of sponsors’ preferred proprietary names prior to launch – a significant improvement over just five years ago that seems driven in part by several new guidance documents.

FDA’s Center for Drug Evaluation & Research is now granting 86% of drug sponsors’ preferred proprietary trade names prior to launch – a significant improvement over just five years ago. Better communication between FDA and drugs sponsors – including the development of several new guidance documents – has resulted in a much more predictable review of proprietary trade names.

Cipla has reported robust growth in the second quarter, buoyed by one-off revenues from the US, but the Indian company sought to temper full-year top-line expectations in view of the strong first-half showing.